Molecular diagnostics and personalized cancer therapy at CancerGen Labs

Our website is primarily aimed at patients and their families, which is why we present medical topics there in a clear, understandable language. This page, on the other hand, is explicitly aimed at specialists, oncologists and hematologists. Our services include our highly specialized diagnostic and therapeutic evaluations, which are based on the latest molecular and genetic technologies. The actual therapy planning and implementation is always carried out by you as the treating or supervising physician. Our analyses serve as a valuable basis for your decisions in order to develop highly precise therapy approaches for your patients.

Our range of services: Molecular diagnostics and therapeutic evaluations to optimize personalized oncology

CancerGen Labs offers specialized molecular diagnostics based on the detailed characterization of solid tumors and hematological malignancies, complemented by comprehensive in vitro tests for therapy evaluation. This combination enables precise analysis of tumor biology and evidence-based assessment of the effectiveness of potential therapies. We precisely analyze the genetic and molecular properties of the tumor tissue or leukemia cells to identify specific therapeutic targets. These well-founded molecular profiles enable you as treating physicians to develop tailored treatment strategies that optimally integrate both innovative targeted therapies and proven procedures such as chemotherapy and radiotherapy.

1. Molecular tumor diagnostics and hematological malignancies (leukemia analysis)
   Our diagnostic procedures rely on state-of-the-art technologies such as next-generation sequencing (NGS), digital PCR and fluorescence in situ hybridization (FISH) to identify clinically relevant mutations, translocations, amplifications and deletions. These highly specific analyses enable precise characterization of the tumor or leukemia at the genomic and proteomic level. The identification of driver mutations such as EGFR, KRAS, BRAF or JAK2 as well as the detection of gene fusions such as ALK and ROS1 provide crucial information for the use of targeted therapies. Our analyses also include the investigation of microsatellite instable tumors (MSI) and tumor mutation burden (TMB) as predictors for immunotherapy.

2. Therapy evaluation and radiosensitivity
   In addition to molecular diagnostics, we offer comprehensive in vitro tests for therapy evaluation. These tests analyze the sensitivity of the tumor to various treatment modalities, including targeted therapies, chemotherapy, immunotherapy and radiotherapy. In radiotherapy in particular, the analysis of radiosensitivity enables the radiation dose to be precisely tailored to the individual tumor characteristics. We test the reaction of tumor cells to specific types of radiation and radiation intensities in order to identify resistance mechanisms and thus maximize therapy efficiency. When making therapy decisions, our analyses provide valuable data for optimally planning the combination of radiotherapy with other therapies.

3. Precision medicine approaches in oncology and hematology
   The personalization of therapy is a central aspect of modern cancer treatment. Our comprehensive molecular and immunological tests allow the individualized adaptation of therapy approaches to the specific genetic and epigenetic profiles of the tumors. This includes the analysis of biomarkers such as PD-L1, BRCA1/2 and HRD to test the suitability of immunotherapies, PARP inhibitors and other targeted drugs. In hematological oncology, we analyze chromosomal aberrations and clonal mutations that are crucial for the prognosis and therapy decision in leukemias and lymphomas. Our tests support you in the selection of optimal therapeutics, including CAR-T cell therapy, and provide crucial insights into the molecular mechanisms behind disease progression.

4. Cancer and leukemia-specific diagnostic and therapy packages
   Our diagnostic and therapeutic evaluations are specifically tailored to different tumor types and hematological malignancies. For solid tumors such as lung cancer, breast cancer and colorectal cancer, we offer comprehensive molecular profiles that enable personalized therapy planning. For hematological malignancies, including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), we offer specialized gene panel tests that uncover clonal evolution and resistance mechanisms. These packages also include tests to determine the tumor microenvironment, which is crucial for immunotherapy, and radioresistance to optimize the effectiveness of radiotherapy.

Cooperation opportunities with clinics and specialists

CancerGen Labs offers you, as medical experts, comprehensive opportunities for collaboration. Our goal is to support you in the optimal therapy planning and diagnostics of your patients, while the treatment and implementation of the therapy is entirely your responsibility. We offer flexible cooperation models: from direct support of the patient to fully internal coordination, where we support your practice or clinic without direct patient interaction . Through this close cooperation, we ensure that you have access to the latest molecular findings and technologies to ensure the best possible treatment for your patients. Together, we can further advance individualized cancer therapy and expand the spectrum of precision medicine. We look forward to working with you.